Glaxo Group Limited vs. Rajiv Mukul

"Patent Rights: Balancing Innovation and Access"

Case Background

- Patent Dispute: Glaxo Group Limited sued Rajiv Mukul and others for allegedly infringing their patent for Rosuvastatin.

- Allegations: Glaxo claimed that the defendants were manufacturing and selling generic versions of Rosuvastatin, violating their patent rights.

Court's Decision

- Injunction: The court granted an interim injunction in favor of Glaxo Group Limited, restraining the defendants from manufacturing and selling generic versions of Rosuvastatin.

- Key Findings: The court found that Glaxo's patent for Rosuvastatin was valid and that the defendants' actions constituted infringement.

Implications

- Patent Protection: The judgment highlights the importance of patent protection for pharmaceutical companies and the need to prevent infringement.

- Generic Drugs: The case also raises questions about the balance between patent protection and access to affordable generic drugs.